ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 661

Topoisomerase-1 Specific T Cells Exhibit a Proinflammatory Th17 Phenotype and Are Associated With Interstitial Lung Disease In Scleroderma

Andrea Fava1, Raffaello Cimbro1, Antony Rosen2, Qing-Rong Liu3, Fredrick M. Wigley2 and Francesco Boin2, 1Division of Rheumatology, Johns Hopkins University, Baltimore, MD, 2Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, 3NIH/NIDA, Baltimore, MD

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: autoantigens and scleroderma, T cells

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Sclerosis, Fibrosing Syndromes and Raynaud's I

Session Type: Abstract Submissions (ACR)

Background/Purpose: Anti-topoisomerase-1 (Topo-1 or Scl70) autoantibodies are present in 30-45% of scleroderma (SSc) patients and identify a more aggressive disease phenotype with worse clinical outcome and reduced survival. While autoreactive T cells may be involved in SSc pathogenesis driving tissue inflammation and damage, no study has to date reliably quantified and functionally characterized topo-1-specific T cells in SSc patients.

Methods: Peripheral blood mononuclear cells from 27 (15 Scl70-positive and 12 Scl70-negative) consecutive patients and 4 healthy donors (HD) were stimulated with topoisomerase-1 purified from baculovirus-infected insect cells in the presence of anti-CD40 blocking antibodies and autologous serum. Topo-1-responsive T cells were defined based on the expression of activation markers CD154 and CD69, and their frequency calculated as percentage of CD4+ cells. The polarized functional phenotype (Th1, Th2, Th17, Th1/17) of autoreactive T cells was further determined by the surface expression of specific chemokine receptors (CXCR3, CCR6, CCR4) and their cytokine secretion profile (IFNγ, IL-4, IL-17) quantified by ELISA and qPCR after cell sorting. Comprehensive clinical data were obtained at the time of blood draws.

Results: Topo-1-reactive CD4+ T cells were found in all topo-1-positive subjects compared to one topo-1-negative patient and no HD [p=<0.001 and p=0.005 respectively] with a frequency ranging between 0.11% and 0.42% of CD4+ T cells. Anti-HLA-DR antibodies effectively inhibited topo-1 presentation and the activation of topo-1-responsive CD4+ T cells. Topo-1-specific T cells exhibited a predominant Th17 phenotype compared to the parent CD4+ T cell population [37±16% vs 8±5%, p=0.001]. Among topo-1-positive patients, higher levels of topo-1-reactive CD4+ T cells were associated with presence of interstitial lung disease [p=0.03], lower forced vital capacity (FVC) [rho=-0.657, p=0.011], and lower carbon monoxide diffusing capacity (DLco) [rho=-0.592, p=0.026].

Conclusion: This study establishes a robust and sensitive assay to measure topo-1-reactive T cells, and suggests that Th17 differentiation may be of importance in SSc pathogenesis.


Disclosure:

A. Fava,
None;

R. Cimbro,
None;

A. Rosen,
None;

Q. R. Liu,
None;

F. M. Wigley,
None;

F. Boin,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/topoisomerase-1-specific-t-cells-exhibit-a-proinflammatory-th17-phenotype-and-are-associated-with-interstitial-lung-disease-in-scleroderma/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology